Plasma levels of plasminogen, fibrinogen and plasmin non-diabetic and smoker patients with coronary artery disease

Coronary artery disease (CAD) is one of the major causes of mortality and morbidity. It is characterized by the activation and aggregation of the platelet, thrombus formation and myocardial infarction. During recent years, many epidemiological studies on risk factors of CAD have been performed which are fibrinogen, lipoprotein (a), and hemocystein as new CAD risk factors. The aim of the present study was to evaluate of plasminogen, fibrinogen and plasmin (PAP) levels in plasma including in patients of non-diabetic and smoker as the hemostatic parameters and their association with CAD to prevent progression of disease.

In this study selected 120 subjects including 60 patients who underwent coronary angiography and 60 controls from blood donors of blood bank who had no history of CAD and liver disease and cancer. To determined Plasma levels plasminogen and PAP used ELISA Procedure (Bioassay technology laboratory kit) and plasma level of fibrinogen used Clauss method by kit of Mahsa yaran.

Plasma levels of plasminogen and plasmin anti plasmin (PAP) in patients with CAD were found to be significantly lower than control group (p

Elevated plasma levels of fibrinogen participate in atherogenesis leading to CAD. These finding suggested plasma level of fibrinogen can be useful as a diagnostic and monitoring marker in patients with CAD. Plasmin and plasminogen deficiency may participate in progressing CAD and thrombus formation and impaired fibrinolysis.